Promising drug trial for pancreatic cancer halted early
NCT ID NCT05442749
First seen Feb 20, 2026 · Last updated May 17, 2026 · Updated 13 times
Summary
This study tested a drug called niraparib as a first treatment for people with metastatic pancreatic cancer that has certain gene changes (HR-deficient). Only 2 people enrolled before the trial was stopped early. The goal was to see if the drug could shrink tumors, but results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, 38043, France
-
Centre Léon Bérard
Lyon, 69373, France
Conditions
Explore the condition pages connected to this study.